世界のパーキンソン病治療薬市場

◆英語タイトル:Global Parkinson’s Disease Drugs Market Outlook 2022
◆商品コード:DATA7100509
◆発行会社(リサーチ会社):RNCOS
◆発行日:2017年8月10日
◆ページ数:100
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single UserUSD3,000 ⇒換算¥330,000見積依頼/購入/質問フォーム
Multi UserUSD4,500 ⇒換算¥495,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はRNCOS社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。RNCOS社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Parkinson’s disease belongs to the group of conditions called motor system disorders. This disease is a result of loss of dopamine producing neurons in the brain. The four primary symptoms of Parkinson’s disease are tremors, rigidity, slowness of movement and postural instability. Although, there is no cure for Parkinson’s disease, several medications are used to suppress the symptoms of the disease.
As per RNCOS report “Global Parkinson’s Disease Drugs Market Outlook 2022”, the global Parkinson’s disease drugs market is anticipated to witness a moderate growth during 2016-2022. This report provides a detailed analysis of the current and future market scenario of the global Parkinson’s disease drugs market. The report provides insight about the major drivers, such as increasing awareness about Parkinson’s disease and its treatment options, research grants and funds, for the global Parkinson’s disease drugs market.

Furthermore, few challenges, such as patent expiry and high cost of treatment, which are hindering the growth of the global Parkinson’s disease drugs market have also been mentioned in the report. In addition, the report also highlights various opportunities available for growth of the global Parkinson’s disease drugs market.

The global Parkinson’s disease drugs market has been segmented on the basis of type of therapy into levodopa therapy, dopamine therapy, MAO-B inhibitor therapy, COMT inhibitor therapy, and other types of therapies. Among all the types, levodopa therapy is the first and most potent treatment for the Parkinson’s disease. The benefits of the medication are witnessed soon after administration.

Apart from these types of therapies, various pharmaceutical and biotech companies are also developing stem cell therapy for the treatment of Parkinson’s disease. Stem cell therapy is an evolving field which makes use of stem cells to treat or prevent a disease or condition, such as Parkinson’s disease. Even a minimal success from this procedure can mean significant improvement in quality of life for patients.

Numerous companies, such as SanBio Inc and International Stem Cell Corp, are carrying out clinical trials for stem cell therapies for the treatment of Parkinson’s disease. Hence, stem cell therapy presents great opportunities for the growth of global Parkinson’s disease drugs market in the coming years.

Based on geography, the report divides the market into North America, Europe, and Asia-Pacific. In 2016, North America accounted for the largest share in the global Parkinson’s disease drugs market. Moreover, the report also highlights various mergers and acquisitions taking place in the global Parkinson’s disease drugs industry. The drugs pipeline of Parkinson’s disease has also been mentioned in the report.

The last section of the report discusses about the prominent players in global Parkinson’s disease drugs market. A brief business overview and financial information about each of these players has been provided, along with their product portfolios and product pipeline. The recent developments of every player have also been presented in the report. Overall, the research contains exhaustive information that will help clients in formulating market strategies and assessing opportunity areas in the global Parkinson’s disease drugs market.

【レポートの目次】

1. Analyst View
2. Research Methodology
3. Parkinson’s Disease: An Overview
4. Market Dynamics
4.1 Drivers
4.1.1 Increasing Funding Support & Research Grants
4.1.2 Increasing Awareness
4.1.3 Rising Healthcare Expenditure
4.1.4 Increasing Life Expectancy
4.2 Challenges
4.2.1 Patent Expiry of Blockbuster Drugs
4.2.2 High Cost of Treatment
4.2.3 Side Effects of Parkinson’s Disease Drugs
4.3 Opportunities
4.3.1 Collaboratios with Academic Institutions for Developing Innovative Solutions
4.3.2 Reduction in “Off” Time to Improve Patient and Economic Outcomes
4.3.3 Growing Geriatric Population
5. Global Parkinson’s Disease Drugs Market Outlook 2022
6. Major Products in Parkinson’s Disease Market
6.1 Duodopa/Duopa
6.2 Azilect
6.3 Mirapex/Mirapex ER
6.4 Requip
6.5 Neupro
6.6 Rytary/Numient
6.7 Xadago
6.8 Nuplazid
7. Market Segmentation by Type of Therapy
7.1 Levodopa Therapy
7.2 Dopamine Agonist Therapy
7.3 MAO-B Inhibitor Therapy
7.4 COMT Inhibitor Therapy
7.5 Other Therapy
8. Market Segmentation by Geography
8.1 North America
8.2 Europe
8.3 Asia-Pacific
9. Trends & Developments
9.1 Stem Cell Therapies – Revolutionizing Parkinson Treatment
9.2 Incessant Launch of Novel Products
10. Mergers & Acquisitions
11. Drugs Pipeline of Parkinson’s Disease
12. Company Profiles
12.1 Abbvie Inc.
12.2 Newron Pharmaceuticals SpA
12.3 Acadia Pharmaceuticals Inc.
12.4 Boehringer Ingelheim International GmbH
12.5 Teva Pharmaceutical Industries Limited
12.6 GlaxoSmithKline plc
12.7 UCB S.A.
12.8 Novartis AG
12.9 Impax Laboratories, Inc.
12.10 Valeant Pharmaceuticals International, Inc.
12.11 Merck & Co., Inc.
12.12 Mylan N.V.
12.13 F. Hoffmann-La Roche Ltd.
12.14 US WorldMeds, LLC

List of Figures:

Figure 4-1: Global – Population 60 Years or Above (Billion), 2015, 2030 & 2050
Figure 5-1: Global – Parkinson’s Disease Drugs Market (Billion US$), 2016 & 2022
Figure 6-1: Global – Sales of Duodopa/Duopa (Billion US$), 2015 & 2016
Figure 6-2: Global – Sales of Azilect (Billion US$), 2015 & 2016
Figure 6-3: Global – Sales of Mirapex/Mirapex ER (Billion US$), 2015 & 2016
Figure 6-4: Global – Sales of Requip (Billion US$), 2015 & 2016
Figure 6-5: Global – Sales of Neupro (Billion US$), 2015 & 2016
Figure 6-6: Global – Sales of Rytary/Numient (Billion US$), 2015 & 2016
Figure 7-1: Global – Parkinson’s Disease Drugs Market by Type of Therapy (%), 2016
Figure 7-2: Global – Levodopa Therapy Market for Parkinson’s Disease (Billion US$), 2016 & 2022
Figure 7-3: Global – Dopamine Agonist Therapy Market for Parkinson’s Disease (Billion US$), 2016 & 2022
Figure 7-4: Global – MAO-B Inhibitor Therapy Market for Parkinson’s Disease (Billion US$), 2016 & 2022
Figure 7-5: Global – COMT Inhibitor Therapy Market for Parkinson’s Disease (Billion US$), 2016 & 2022
Figure 7-6: Global – Other Therapy Market for Parkinson’s Disease (Billion US$), 2016 & 2022
Figure 8-1: Global – Parkinson’s Disease Drugs Market by Geography (%), 2016
Figure 8-2: North America – Parkinson’s Disease Drugs Market (Billion US$), 2016 & 202
Figure 8-3: North America – Population 60 Years or Above (Million), 2015, 2030 & 2050
Figure 8-4: Europe – Parkinson’s Disease Drugs Market (Billion US$), 2016 & 2022
Figure 8-5: Asia-Pacific – Parkinson’s Disease Drugs Market (Billion US$), 2016 & 2022
Figure 12-1: Abbvie Inc. – Breakup of Revenue by Geography (%), 2016
Figure 12-2: Boehringer Ingelheim International GmbH – Breakup of Sales by Business Segment (%), 2016
Figure 12-3: Boehringer Ingelheim International GmbH – Breakup of Sales by Geography (%), 2016
Figure 12-4: Teva Pharmaceutical Industries Limited – Breakup of Revenue by Business Segment (%), 2016
Figure 12-5: Teva Pharmaceutical Industries Limited – Breakup of Revenue by Geography (%), 2016
Figure 12-6: GlaxoSmithKline plc – Breakup of Group Turnover by Business Segment (%), 2016
Figure 12-7: GlaxoSmithKline plc – Breakup of Group Turnover by Geography (%), 2016
Figure 12-8: UCB S.A. – Breakup of Revenue by Geography (%), 2016
Figure 12-9: Novartis AG – Breakup of Sales by Business Segment (%), 2016
Figure 12-10: Novartis AG – Breakup of Pharmaceuticals Division Sales by Segment (%), 2016
Figure 12-11: Novartis AG – Breakup of Sales by Geography (%), 2016
Figure 12-12: Impax Laboratories, Inc. – Breakup of Revenue by Business Segment (%), 2016
Figure 12-13: Valeant Pharmaceuticals International, Inc. – Breakup of Revenue by Business Segment (%), 2016
Figure 12-14: Valeant Pharmaceuticals International, Inc. – Breakup of Revenue by Geography (%), 2016
Figure 12-15: Merck & Co., Inc. – Sales by Business Segments (%), 2016
Figure 12-16: Merck & Co., Inc. – Sales by Geography (%), 2016
Figure 12-17: Mylan N.V. – Breakup of Revenue by Geography (%), 2016
Figure 12-18: F. Hoffmann-La Roche Ltd. – Breakup of Sales by Business Segment (%), 2016

List of Tables:

Table 10-1: Mergers, Acquisitions & Collaborations in Parkinson’s Disease Drugs Market (2015-2017)
Table 11-1: Global – Drugs Pipeline of Parkinson’s Disease
Table 12-1: Abbvie Inc. – Key Financials (Billion US$), 2014-2016
Table 12-2: Abbvie Inc. – Marketed Parkinson’s Disease Products
Table 12-3: Abbvie Inc. – Parkinson’s Disease Products in Pipeline
Table 12-4: Newron Pharmaceuticals SpA – Key Financials (Million US$), 2014-2016
Table 12-5: Newron Pharmaceuticals SpA – Marketed Parkinson’s Disease Products
Table 12-6: Newron Pharmaceuticals SpA – Parkinson’s Disease Products in Pipeline
Table 12-7: Acadia Pharmaceuticals Inc. – Key Financials (Million US$), 2014-2016
Table 12-8: Acadia Pharmaceuticals Inc. – Marketed Parkinson’s Disease Products
Table 12-9: Boehringer Ingelheim International GmbH – Key Financials (Billion US$), 2014-2016
Table 12-10: Boehringer Ingelheim International GmbH – Marketed Parkinson’s Disease Products
Table 12-11: Teva Pharmaceutical Industries Limited – Key Financials (Billion US$), 2014-2016
Table 12-12: Teva Pharmaceutical Industries Limited – Marketed Parkinson’s Disease Products
Table 12-13: GlaxoSmithKline plc – Key Financials (Billion US$), 2014-2016
Table 12-14: GlaxoSmithKline plc – Marketed Parkinson’s Disease Products
Table 12-15: UCB S.A. – Key Financials (Billion US$), 2014-2016
Table 12-16: UCB S.A. – Marketed Parkinson’s Disease Products
Table 12-17: UCB S.A. – Parkinson’s Disease Products in Pipeline
Table 12-18: Novartis AG – Key Financials (Billion US$), 2014-2016
Table 12-19: Novartis AG – Marketed Parkinson’s Disease Products
Table 12-20: Impax Laboratories, Inc. – Key Financials (Million US$), 2014-201
Table 12-21: Impax Laboratories, Inc. – Marketed Parkinson’s Disease Products
Table 12-22: Impax Laboratories, Inc. – Parkinson’s Disease Products in Pipeline
Table 12-23: Valeant Pharmaceuticals International, Inc. – Key Financials (Billion US$), 2014-2016
Table 12-24: Valeant Pharmaceuticals International, Inc. – Marketed Parkinson’s Disease Products
Table 12-25: Merck & Co., Inc. – Key Financials (Million US$), 2014-2016
Table 12-26: Merck & Co., Inc. – Marketed Parkinson’s Disease Products
Table 12-27: Mylan N.V. – Key Financials (Billion US$), 2014-2016
Table 12-28: Mylan N.V. – Marketed Parkinson’s Disease Products
Table 12-29: F. Hoffmann-La Roche Ltd. – Key Financials (Billion US$), 2014-2016
Table 12-30: F. Hoffmann-La Roche Ltd. – Marketed Parkinson’s Disease Products
Table 12-31: F. Hoffmann-La Roche Ltd. – Parkinson’s Disease Products in Pipeline
Table 12-32: US WorldMeds, LLC – Marketed Parkinson’s Disease Products
Table 12-33: US WorldMeds, LLC – Parkinson’s Disease Products in Pipeline



【レポートのキーワード】

パーキンソン病治療薬

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界のパーキンソン病治療薬市場(Global Parkinson’s Disease Drugs Market Outlook 2022)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆